Renal cell carcinomaMolecular therapyAnti-angiogenic therapySunitinibSorafenibOver the past 5years, the treatment of renal cell carcinoma (RCC) has undergone a dramatic change. Surgery in the early disease stages is still the only known curative treatment modality, while palliative nephrectomy, nephron ...
Renal Cell Carcinoma. NewYork, NY, USA: Springer; 2012.Vankayala H, Lorusso P, Vaishampayan UN. C-MET as a novel target for the treatment of renal cell carcinoma. In: Figlin RA, Rathmell WK, Rini BI, editors. Renal Cell Carcinoma. New York, NY, USA: Springer; 2012....
Introduction: In the evolving treatment scenario of metastatic renal cell carcinoma, cabozantinib is gaining increasing attention, presenting as a cornerstone therapy, both as a monotherapy and in combination with immune-checkpoint inhibitors.Areas covered: In this review, the authors explore the role of...
(2011) Bevacizumab plus interferon-a versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig 31(7): 507 – 517 Rini BI, Escudier B, Tomczak P (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal ...
If the results show that you have renal cell carcinoma, your doctor will find out what stage it’s in, so you can decide on the best treatment options. The stage of cancer depends on how large your tumor is and whether the cancer has spread to other parts of your body. You may have...
In KEYNOTE-564, when Keytruda was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving Keytruda ; the serious adverse reactions (≥1%) were acute kidney injury, adrenal insufficiency, p...
EP: 2.First-Line Treatment Strategies in Renal Cell Carcinoma Now Viewing EP: 3.Limitations in Treatment of Metastatic Renal Cell Carcinoma EP: 4.CheckMate 9ER Trial Updates EP: 5.CheckMate 9ER: Quality of Life Data and Treatment Implications in Advanced RCC ...
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial growth factor A (VEGF-A) production that induces a specific vascular phenotype. We previously reported that this phenotype may allow shedding of multicellular tumor fragments into the circulation...
Tian Zhang, MD, MHS, and Moshe Orenstein, MD, MA, recall data from two clinical trials for first-line treatment of advanced renal cell carcinoma: CheckMate-9ER and CheckMate-214.This is a modal window. The Playback API request failed for an unknown reason...
Eric Jonasch, MD:Hi. I'm Dr Eric Jonasch. I'm a medical oncologist at MD Anderson Cancer Center. I'm joined by Dr Katy Beckermann, who's a medical oncologist at Vanderbilt. Our topic today is patients with favorable-risk advanced renal cell carcinoma. How should we treat these individu...